Activation of Nuclear Factor-κB by Depolarization and Ca2+ Influx in MIN6 Insulinoma Cells
- From the Washington University School of Medicine, Division of Endocrinology, Diabetes and Metabolism, St. Louis, Missouri
Abstract
The purpose of the current study was to determine whether nuclear factor-κB (NF-κB) activation is a component of the depolarization/Ca2+-dependent signaling in β-cells. MIN6 cells were transfected with a plasmid containing five tandem repeats of NF-κB binding sites linked to a luciferase reporter. The results of these experiments showed that KCl induced depolarization-activated NF-κB-dependent transcription (3.8-fold at 45 mmol/l, P < 0.01) in a concentration-dependent manner. Tumor necrosis factor-α (TNF-α), a known inducer of NF-κB signaling, activated this construct by 3.4-fold (P < 0.01). The response of NF-κB to depolarization was inhibited by the Ca2+-channel blocker verapamil and by the mitogen-activated protein kinase kinase (MEK) inhibitor PD98059 (70 and 62%, respectively). TNF-α, glucose, and KCl treatment resulted in inhibitory κBα degradation by Western blot analysis. TNF-α treatment and depolarization activation of NF-κB differed significantly in that TNF-α activation was not blocked by PD98059. Transfection with PKA, MEK, and MEK kinase induced NF-κB-dependent transcription by 20-, 90-, and 300-fold, respectively, suggesting that these pathways contribute to the activation in the depolarization response. These findings demonstrate that depolarization/Ca2+ influx, as well as TNF-α treatment, can activate NF-κB-dependent transcription in pancreatic β-cells, but by different signaling pathways. The current studies show that Ca2+ signals in pancreatic β-cells can activate transcription factors involved in the regulation of cell cycle and apoptosis. These findings now add NF-κB to the list of depolarization-induced transcription factors in pancreatic β-cells.
Footnotes
-
Address correspondence and reprint requests to Ernesto Bernal-Mizrachi, 660 S. Euclid Ave., Campus Box 8127, St. Louis, MO 63110. E-mail: ebernal{at}im.wustl.edu.
Received for publication 19 March 2002 and accepted in revised form 1 June 2002.
CaMK, CaM kinase; DMEM, Dulbecco’s modified Eagle’s medium; ERK, extracellular-regulated kinase; FBS, fetal bovine serum; IκB, inhibitory κB; KRBH, Krebs-Ringer bicarbonate HEPES; MAPK, mitogen-activated protein kinase; MEK, MAPK kinase; MEKK, MEK kinase; NF-κB, nuclear factor-κB; PI, phosphatidylinositol; PKA, protein kinase A; PKC, protein kinase C; TNF-α, tumor necrosis factor-α.
The symposium and the publication of this article have been made possible by an unrestricted educational grant from Servier, Paris.
- DIABETES














